Tenderwize
Wróć do wyszukiwania

Open House Rebate Agreement for Interferon beta-1a (Avonex)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 584 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Interferon beta-1a, Fertigarzneimittelbezeichnung Avonex(R), ATC L03AB07

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

10 / 100

Czynniki ryzyka

The open-house agreement may be automatically displaced by any subsequent nationwide or regional rebate contract for th...

The buyer may terminate the agreement with one month's notice without cause.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Non-exclusive rebate agreements for Interferon beta-1a (Avonex(R)), ATC L03AB07, under § 130a Abs. 8 SGB V.
  • Contracts are identical and not individually negotiable.
Pokaż pełne podsumowanie

This is an open-house (non-competitive) procedure by AOK Bayern for non-exclusive rebate agreements on the pharmaceutical product Interferon beta-1a (Avonex(R)), ATC L03AB07. Any eligible pharmaceutical company can join under identical, non-negotiable terms. Contracts run from 01.06.2026 to 31.05.2028, with the possibility to sign at any time until 03.04.2028. The procedure is not subject to procurement law; no award criteria apply. Only a signed self-declaration of reliability is required for eligibility. Documents must be submitted in German, either in paper (two original copies) or electronically with a qualified electronic signature. No estimated contract value is provided. Risks include automatic termination if superseded by another rebate contract and the possibility of cancellation with one month's notice.

Ryzyka

The open-house agreement may be automatically displaced by any subsequent nationwide or regional rebate contract for th...

The buyer may terminate the agreement with one month's notice without cause.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible.

Certifications

  • Documents must be in German; non-German documents require a certified translation.

Administrative

  • Submission of a signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit).

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open House Rebate Agreement for Interferon beta-1a (Avonex)

Non-exclusive rebate agreement for Interferon beta-1a (Avonex(R)), ATC L03AB07. Open to all eligible pharmaceutical companies. Contract period 01.06.2026 – 31.05.2028. No award criteria; all eligible participants receive a contract.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

May 2026 - May 2028

Kategoria

Pharmaceutical products

Termin

Deadline Apr 03, 2028

Szczegóły zamówienia

Data publikacji
14 Apr 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
254339-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30